12-week, multi-center, randomized, human body application test for the efficacy evaluation of rTG-Omega3 in dry eye disease accompanied by Meibomian Gland Dysfunction(MGD).

Taejoon Pharm0 个研究点目标入组 140 人开始时间: 待定最近更新: 2023年2月8日

试验速览

暂无简介。

•1. A person who has been diagnosed with Meibomian gland dysfunction (MGD) within 3 months(based on the latest surgery) of undergoing binocular cataract surgery(at least one of the three criteria below is satisfied).
•1) During eyelid compression, the discharge of meibomian glands is reduced, showing cloudy, toothpaste-like secretions, or viscous secretions.
•2) Two or more Telangiectasia on the edge of the eyelid.
•3) Two or more Meibomian Glands Orfices are blocked
•*Drugs/treatment materials used during cataract surgery are subject to institutional standards.
•2 Those with a Tearfilm Break-Up Time (TBUT) of less than 10 seconds
•3. A person who agrees to participate in this human body application test before the human body application test begins and prepares a written consent form.

•- Those who are judged to be inappropriate to participate in this human application test under the judgment of nvestigators

发起方

Taejoon Pharm